UPCC 04424 A Phase 1 FirstinHuman Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV787 in Adult Subjects with Acute Myeloid Leukemia (AML)

Enrolling By Invitation
99 years and younger
All
Phase N/A
1 Location

Brief description of study

Please refer to Protocol Section1.1.1 (Objectives and Endpoints). Please refer to Protocol Section1.1.1 (Objectives and Endpoints). Please refer to Protocol Section1.1.1 (Objectives and Endpoints).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Medical Research
  • Age: - 99 Years
  • Gender: All

TBD

Updated on 12 Jun 2024. Study ID: 855405
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center